240 related articles for article (PubMed ID: 26997225)
1. Staphylococcal Nuclease and Tudor Domain Containing 1 (SND1 Protein) Promotes Hepatocarcinogenesis by Inhibiting Monoglyceride Lipase (MGLL).
Rajasekaran D; Jariwala N; Mendoza RG; Robertson CL; Akiel MA; Dozmorov M; Fisher PB; Sarkar D
J Biol Chem; 2016 May; 291(20):10736-46. PubMed ID: 26997225
[TBL] [Abstract][Full Text] [Related]
2. SND1 affects proliferation of hepatocellular carcinoma cell line SMMC-7721 by regulating IGFBP3 expression.
Yin J; Ding J; Huang L; Tian X; Shi X; Zhi L; Song J; Zhang Y; Gao X; Yao Z; Jing X; Yang J
Anat Rec (Hoboken); 2013 Oct; 296(10):1568-75. PubMed ID: 23878061
[TBL] [Abstract][Full Text] [Related]
3. Multifunction protein staphylococcal nuclease domain containing 1 (SND1) promotes tumor angiogenesis in human hepatocellular carcinoma through novel pathway that involves nuclear factor κB and miR-221.
Santhekadur PK; Das SK; Gredler R; Chen D; Srivastava J; Robertson C; Baldwin AS; Fisher PB; Sarkar D
J Biol Chem; 2012 Apr; 287(17):13952-8. PubMed ID: 22396537
[TBL] [Abstract][Full Text] [Related]
4. Posttranscriptional Inhibition of Protein Tyrosine Phosphatase Nonreceptor Type 23 by Staphylococcal Nuclease and Tudor Domain Containing 1: Implications for Hepatocellular Carcinoma.
Jariwala N; Mendoza RG; Garcia D; Lai Z; Subler MA; Windle JJ; Mukhopadhyay ND; Fisher PB; Chen Y; Sarkar D
Hepatol Commun; 2019 Sep; 3(9):1258-1270. PubMed ID: 31497746
[TBL] [Abstract][Full Text] [Related]
5. Loss of the methylarginine reader function of SND1 confers resistance to hepatocellular carcinoma.
Wright T; Wang Y; Stratton SA; Sebastian M; Liu B; Johnson DG; Bedford MT
Biochem J; 2023 Nov; 480(22):1805-1816. PubMed ID: 37905668
[TBL] [Abstract][Full Text] [Related]
6. Increased RNA-induced silencing complex (RISC) activity contributes to hepatocellular carcinoma.
Yoo BK; Santhekadur PK; Gredler R; Chen D; Emdad L; Bhutia S; Pannell L; Fisher PB; Sarkar D
Hepatology; 2011 May; 53(5):1538-48. PubMed ID: 21520169
[TBL] [Abstract][Full Text] [Related]
7. SND1 acts as an anti-apoptotic factor via regulating the expression of lncRNA UCA1 in hepatocellular carcinoma.
Cui X; Zhao C; Yao X; Qian B; Su C; Ren Y; Yao Z; Gao X; Yang J
RNA Biol; 2018; 15(10):1364-1375. PubMed ID: 30321081
[TBL] [Abstract][Full Text] [Related]
8. RASSF1A expression inhibits the growth of hepatocellular carcinoma from Qidong County.
Xue WJ; Li C; Zhou XJ; Guan HG; Qin L; Li P; Wang ZW; Qian HX
J Gastroenterol Hepatol; 2008 Sep; 23(9):1448-58. PubMed ID: 17683489
[TBL] [Abstract][Full Text] [Related]
9. Tumor necrosis factor α-induced protein 1 as a novel tumor suppressor through selective downregulation of CSNK2B blocks nuclear factor-κB activation in hepatocellular carcinoma.
Xiao Y; Huang S; Qiu F; Ding X; Sun Y; Wei C; Hu X; Wei K; Long S; Xie L; Xun Y; Chen W; Zhang Z; Liu N; Xiang S
EBioMedicine; 2020 Jan; 51():102603. PubMed ID: 31901862
[TBL] [Abstract][Full Text] [Related]
10. Methylation-regulated miR-124-1 suppresses tumorigenesis in hepatocellular carcinoma by targeting CASC3.
Xu L; Dai W; Li J; He L; Wang F; Xia Y; Chen K; Li S; Liu T; Lu J; Zhou Y; Wang Y; Guo C
Oncotarget; 2016 May; 7(18):26027-41. PubMed ID: 27029030
[TBL] [Abstract][Full Text] [Related]
11. TRIM52 up-regulation in hepatocellular carcinoma cells promotes proliferation, migration and invasion through the ubiquitination of PPM1A.
Zhang Y; Tao R; Wu SS; Xu CC; Wang JL; Chen J; Yu YS; Tang ZH; Chen XH; Zang GQ
J Exp Clin Cancer Res; 2018 Jun; 37(1):116. PubMed ID: 29898761
[TBL] [Abstract][Full Text] [Related]
12. The chemokine receptor CCR10 promotes inflammation-driven hepatocarcinogenesis via PI3K/Akt pathway activation.
Wu Q; Chen JX; Chen Y; Cai LL; Wang XZ; Guo WH; Zheng JF
Cell Death Dis; 2018 Feb; 9(2):232. PubMed ID: 29445190
[TBL] [Abstract][Full Text] [Related]
13. MiR-6875-3p promotes the proliferation, invasion and metastasis of hepatocellular carcinoma via BTG2/FAK/Akt pathway.
Xie Y; Du J; Liu Z; Zhang D; Yao X; Yang Y
J Exp Clin Cancer Res; 2019 Jan; 38(1):7. PubMed ID: 30621734
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the GNMT-HectH9-PREX2 tripartite relationship in the pathogenesis of hepatocellular carcinoma.
Li CH; Yen CH; Chen YF; Lee KJ; Fang CC; Zhang X; Lai CC; Huang SF; Lin HK; Arthur Chen YM
Int J Cancer; 2017 May; 140(10):2284-2297. PubMed ID: 28205209
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of cancer susceptibility candidate 2 inhibited progression of hepatocellular carcinoma cells.
Gao X; Du H; Zhang R; Li C; Wang H; Xuan Q; Liu D
J Cell Physiol; 2019 Jun; 234(6):9008-9018. PubMed ID: 30362539
[TBL] [Abstract][Full Text] [Related]
16. FAM134B induces tumorigenesis and epithelial-to-mesenchymal transition via Akt signaling in hepatocellular carcinoma.
Zhang ZQ; Chen J; Huang WQ; Ning D; Liu QM; Wang C; Zhang L; Ren L; Chu L; Liang HF; Fan HN; Zhang BX; Chen XP
Mol Oncol; 2019 Apr; 13(4):792-810. PubMed ID: 30556279
[TBL] [Abstract][Full Text] [Related]
17. SND1 overexpression deregulates cholesterol homeostasis in hepatocellular carcinoma.
Navarro-Imaz H; Rueda Y; Fresnedo O
Biochim Biophys Acta; 2016 Sep; 1861(9 Pt A):988-996. PubMed ID: 27238764
[TBL] [Abstract][Full Text] [Related]
18. DNASE1L3 inhibits hepatocellular carcinoma by delaying cell cycle progression through CDK2.
Sun J; Wang X; Shen Q; Wang M; Chen S; Zhang X; Huang Y; Zhang Z; Li W; Yuan Y; Huang Z
Cell Oncol (Dordr); 2022 Dec; 45(6):1187-1202. PubMed ID: 36327092
[TBL] [Abstract][Full Text] [Related]
19. APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target.
Chen H; Wong CC; Liu D; Go MYY; Wu B; Peng S; Kuang M; Wong N; Yu J
Theranostics; 2019; 9(18):5246-5260. PubMed ID: 31410213
[No Abstract] [Full Text] [Related]
20. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
